Synthetic lethality and collateral lethality are two well-validated conceptual strategies for identifying therapeutic targets in cancers with tumour-suppressor gene deletions 1-3 . Here, we explore an approach to identify potential synthetic-lethal interactions by screening mutually exclusive deletion patterns in cancer genomes. We sought to identify 'synthetic-essential' genes: those that are occasionally deleted in some cancers but are almost always retained in the context of a specific tumour-suppressor deficiency. We also posited that such synthetic-essential genes would be therapeutic targets in cancers that harbour specific tumour-suppressor deficiencies. In addition to known synthetic-lethal interactions, this approach uncovered the chromatin helicase DNA-binding factor CHD1 as a putative synthetic-essential gene in PTEN-deficient cancers. In PTEN-deficient prostate and breast cancers, CHD1 depletion profoundly and specifically suppressed cell proliferation, cell survival and tumorigenic potential. Mechanistically, functional PTEN stimulates the GSK3β-mediated phosphorylation of CHD1 degron domains, which promotes CHD1 degradation via the β-TrCP-mediated ubiquitination-proteasome pathway. Conversely, PTEN deficiency results in stabilization of CHD1, which in turn engages the trimethyl lysine-4 histone H3 modification to activate transcription of the pro-tumorigenic TNF-NF-κB gene network. This study identifies a novel PTEN pathway in cancer and provides a framework for the discovery of 'trackable' targets in cancers that harbour specific tumour-suppressor deficiencies.
. In mouse models, prostate-specific deletion of Pten (Pten pc−/− ) results in prostatic intraepithelial neoplasia, which may progress to high-grade adenocarcinoma after a long latency period 5 , a pattern consistent with the loss of PTEN acting as a key initiation event in prostate cancer development. To date, therapeutic targeting of the PTEN-PI3K-AKT pathway has yielded meagre clinical benefit, prompting continued efforts to identify obligate effectors of this important pathway in order to identify effective therapeutic targets for PTEN-deficient cancers.
The notion of targeting synthetic-lethal vulnerabilities in cancer has been validated in the treatment of cancers that harbour specific loss-offunction mutations 1, 6 . One celebrated example is the effectiveness of poly(ADP)-ribose polymerase (PARP) inhibitors in BRCA-deficient tumours 2, 7 . More recently, collateral lethality has emerged as another target-discovery strategy for cancers harbouring tumour-suppressor gene deletions that also delete neighbouring genes encoding functionally redundant yet essential activities, thereby creating cancerspecific vulnerabilities 3, 8 . Genomic analyses have also been helpful in identifying functional interactions of components in specific pathways that show mutually exclusive patterns of genomic alterations. Such epistatic patterns include components of the retinoblastoma (Rb) or p53 pathways, in which alterations in one gene in the pathway typically alleviates genetic pressure to alter another driver in the same pathway, consistent with minimal additional selective advantage to the cancer cell 9, 10 . Using The Cancer Genome Atlas (TCGA) database, we sought to establish and validate an approach for identifying potential syntheticlethal interactions in cancer by screening for mutually exclusive deletion patterns in the cancer genome. More specifically, we searched for genes that might occasionally be deleted in some cancers (that is, non-essential genes) but that are always retained in the context of deletion of a specific tumour suppressor, reasoning that the retained gene might be required for executing the cancer-promoting actions in the context of a specific tumour-suppressor deficiency (that is, a syntheticessential gene). By extension, we posited that inhibition of these synthetic-essential genes would impair the survival and tumorigenic potential of cancer cells harbouring the specific tumour-suppressor deficiency. Here, we focused on prostate cancer owing to the frequent and early deletion of the PTEN tumour suppressor and the paucity of actionable 'oncogene' targets in prostate cancer.
The well established synthetic-lethal interaction of BRCA1 and PARP1 provides a measure of validation for our approach, since a mutually exclusive deletion pattern of BRCA1 and PARP1 is readily observed in the prostate cancer TCGA database (Extended Data Fig. 1a) . Similarly, consistent with preclinical and clinical studies suggesting that PTEN deficiency sensitizes prostate, colorectal and endometrial cancer cells to PARP inhibitors 11, 12 , we observed a synthetic-essential relationship between PTEN and PARP1 (Extended Data Fig. 1b) . Another mutually exclusive deletion pattern in prostate cancer points to an interaction between PTEN and polo-like kinase 4 (PLK4) (Extended Data  Fig. 1b ). This observation aligns well with the single-agent anti-tumour activity of the PLK4 inhibitor CFI-400945 and its capacity to induce the regression of PTEN-deficient cancers, compared with PTEN-intact cancer cells 13 . Together, these circumstantial data prompted us to speculate that druggable essential dependencies (synthetic-essential genes) of specific tumour-suppressor gene deficiencies might be uncovered by scanning the patterns of cancer genome deletions.
Large-scale genomic analyses of TCGA and other prostate cancer databases identified CHD1 (5q21 locus) as a locus that is deleted in some human prostate cancer cases (7-10%) [14] [15] [16] , but is consistently retained in PTEN-deficient prostate cancer (Fig. 1a and Extended Data Fig. 1c ). In addition, the pattern of mutual exclusivity with PTEN deletion was observed for CHD1 but not for other CHD homologues (Extended Data Fig. 1d ). The PTEN-CHD1 relationship was reinforced by the strong negative correlation observed between CHD1 and PTEN expression by immunohistochemistry analysis of 127 prostatic hyperplasia and cancer tissue microarray samples (P = 0.001, Fig. 1b and Extended Data Fig. 2a, b) . CHD1 deletion per se does not appear to play a significant role in prostate cancer development, as indicated by the lack of neoplasia in a tissue recombinant model using mouse prostate epithelial progenitor or stem cells in which CHD1 is deleted 17 . Rather, CHD1 expression correlates positively with a high Gleason grade (P = 0.006, Fig. 1c and Extended Data Fig. 2c ) and is increased in neoplastic Pten-deficient mouse prostatic epithelium compared to wild-type controls (Extended Data Fig. 2d, e) . Collectively, these observations prompted us to consider the possibility that CHD1 may be required for the progression of prostate cancer driven by the loss of PTEN.
To test the above hypothesis, we carried out short hairpin RNA (shRNA)-mediated depletion or CRISPR-directed nullizygous mutation of CHD1 in four PTEN-deficient prostate cancer cell lines (shRNA depletion in human LNCaP and PC-3 prostate cancer cell lines, and in mouse Pten/Smad4-null and PtenCaP8 prostate cancer cell lines; CRISPR nullizygous mutation in the LNCaP cell line). In these models, CHD1 suppression inhibited colony formation and induced cell death ( Fig. 1d and Extended Data Fig. 2f-j) , but it had a minimal effect on cell migration (Extended Data Fig. 2k) . Moreover, CHD1 depletion attenuated the growth of tumours derived from PC-3 and LNCaP cells in vivo (Fig. 1e and Extended Data Fig. 2l, m) and, correspondingly, these tumours exhibited a marked reduction in cell proliferation (as measured by Ki67 levels) and increase in apoptosis (as measured by caspase-3 levels) ( Fig. 1f and Extended Data Fig. 2n) . Similarly, administration of a short interfering RNA targeting CHD1 (siCHD1) in established PTEN-deficient patient-derived xenograft (PDX) tumours attenuated tumour progression (Extended Data Fig. 2o, p) . However, CHD1 depletion had a minimal effect on colony formation or tumour growth of the PTEN-intact prostate cancer cell lines 22Rv1, RWPE-2 and DU145 ( Fig. 1g and Extended Data Fig. 3a-d) . By contrast, CRISPR-mediated knockout of PTEN in DU145 cells sensitized the cells to CHD1 depletion both in vitro and in vivo ( Fig. 1g and Extended Data Fig. 3c, d ). Together, these data support the view that CHD1 is a synthetic-essential gene that is required for tumour growth of PTENnull prostate cancer, a functional relationship consistent with the mutually exclusive pattern of PTEN and CHD1 deletions.
Exploration of the functional relationship between PTEN and CHD1 revealed that PTEN re-expression in PTEN-null prostate cancer cell lines led to a substantial decrease in levels of CHD1 protein, but not mRNA ( Fig. 2a and Extended Data Fig. 3e ). Correspondingly, transient ectopic expression of GFP-PTEN suppressed CHD1 in PC-3 cells at the single-cell level (Fig. 2b) . Time-course studies revealed that treatment with the AKT inhibitor MK2206 reduced CHD1 protein levels over a 6-h period (Fig. 2c) and that PTEN re-expression reduced the halflife of CHD1 protein (Extended Data Fig. 3f) , supporting a role for letter reSeArCH the PTEN-AKT axis in the control of CHD1 protein levels. Moreover, CHD1 was more stable in PTEN-deficient cells than in PTEN-intact cells (Extended Data Fig. 3f-h ). To explore the mechanisms governing CHD1 protein levels, we treated the PTEN wild-type benign prostatic hyperplasia epithelial cell line BPH1 with the proteasome inhibitor MG132, resulting in the marked accumulation of CHD1 in a timedependent manner (Fig. 3a) . Moreover, endogenous CHD1 was modified by ubiquitination (Extended Data Fig. 4a ) and PTEN overexpression greatly enhanced CHD1 ubiquitination (Fig. 3b) . Together, these data suggest that CHD1 degradation is controlled through the ubiquitinationproteasome pathway in a PTEN-dependent manner.
To identify a specific E3 ligase that governs CHD1 protein stability, we performed consensus-sequence scanning of multiple E3 ligase interaction domains and identified two evolutionarily conserved putative β -TrCP consensus-binding motifs (DSGXXS) at the N terminus of CHD1-residues 23-28 (motif 1, DSGSAS) and 53-58 (motif 2, DSGSES) ( Fig. 3c and Extended Data Fig. 4b ). β -TrCP is an F-box protein that acts as the substrate-recognition subunit for the SCF β-TrCP (Skp1-Cullin1-F-box protein) E3 ubiquitin ligases, which mediate the ubiquitination and proteasomal degradation of various substrates, including β -catenin, Yap and IKB [18] [19] [20] . The CHD1-β -TrCP link was confirmed by documentation of the endogenous interaction of CHD1 and β -TrCP using co-immunoprecipitation ( Fig. 3d ) and by the fact that β -TrCP overexpression resulted in reduced CHD1 protein levels and enhanced CHD1 ubiquitination (Fig. 3e , f and Extended Data Fig. 4c ). Conversely, shRNA-mediated depletion of β -TrCP caused accumulation of CHD1 and inhibited its ubiquitination (Extended Data Fig. 4d , e). To investigate whether the β -TrCP binding motifs of CHD1 were involved in the regulation of CHD1 protein stability, we introduced wild-type V5-peptide-tagged CHD1 and two β -TrCPbinding motif mutants (DAGXXA) into BPH1 cells, and then analysed the half-life, ubiquitination and β -TrCP interaction of CHD1. These experiments established that motif 2 (DSGSES) serves as the major β -TrCP-binding motif that contributes to CHD1 ubiquitination and degradation (Extended Data Fig. 4f-h ).
β -TrCP recognizes and interacts specifically with phosphorylated substrates 21 . Our analysis of CHD1 showed that both β -TrCP-binding motifs harbour a GSK3β consensus sequence (SXXXS; Extended Data Fig. 4i ). Since GSK3β is a direct target of AKT and is inhibited upon AKT activation, we anticipated that PTEN loss would impair GSK3β activity, resulting in decreased CHD1 phosphorylation and subsequent ubiquitination. In line with this possibility, overexpression of GSK3β and its constitutively active mutant (S9A) in LNCaP cells increased the phosphorylation of CHD1 (Fig. 3g ). This connection was reinforced by the observed endogenous interaction between GSK3β and CHD1 (Extended Data Fig. 4j ), as well as by a decrease in CHD1 levels reduced by enforced expression of GSK3β (Fig. 3h) . Finally, treatment with CHIR-99021, an inhibitor of GSK3β , decreased CHD1 ubiquitination ( Fig. 3i ) and blocked the negative effect of PTEN expression on CHD1 protein stability (Extended Data Fig. 4k ). Together, these data establish that the PTEN-AKT-GSK3β pathway regulates CHD1 degradation via the β -TrCP-mediated ubiquitination-proteasome pathway.
Trimethylation of histone H3 at lysine 4 (H3K4me3) is associated with transcriptional activation and CHD1 selectively recognizes and . f, 293T cells were transfected with Flag-tagged β -TrCP and HA-tagged ubiquitin; endogenous CHD1 was immunoprecipitated and CHD1 ubiquitination was detected. g, HA-tagged wild-type (WT) and constitutively active mutant (S9A) GSK3β were transfected into LNCaP cells and phosphorylated and unphosphorylated CHD1 proteins were separated using phos-tag gel by immunoblot. Total CHD1 protein was used as a loading control, C-Myc as a positive control. h, Immunoblot of CHD1 in LNCaP cells transfected with HA-tagged GSK3β . β -actin was used as a loading control. i, HA-tagged ubiquitin was transfected into 293T cells, followed by treatment with 2 μ M CHIR (at 24 h) and 10 μ M MG132 (at 8 h) and detection of CHD1 ubiquitination by immunoprecipitation and immunoblot. Representative data of triplicate experiments are shown.
binds to H3K4me3 to activate gene transcription 22 . In addition, CHD1 is involved in the maintenance of open chromatin and cooperates with H3K4me3 to control the pluripotency of mouse embryonic stem cells 23 . Correspondingly, co-immunoprecipitation studies in BPH1 cells confirmed that CHD1 binds to H3K4me3 (Extended Data Fig. 5a ) and CHD1 depletion in LNCaP and PC-3 cells revealed a substantial reduction in the H3K4me3 mark (Extended Data Fig. 5b, c) . To identify the downstream transcriptional targets and pathways of CHD1 and H3K4me3 in PTEN-null prostate cancer cells, we performed chromatin immunoprecipitation followed by sequencing (ChIP-seq) in control and CHD1-knockdown PC-3 cells. ChIP-seq identified a total of 8,468 CHD1-binding sites and 26,826 H3K4me3-enriched regions in control PC-3 cells, with 58.6% of CHD1 peaks overlapping with H3K4me3 peaks (Fig. 4a) . In total, 81.4% of CHD1-binding sites showed reduced peak values in CHD1-depleted PC-3 cells, validating our experimental methodology ( Fig. 4b and Extended Data Fig. 5d) . Notably, 77.5% of the peak values of regions enriched for H3K4me3 were concomitantly diminished in CHD1-depleted PC-3 cells (Fig. 4b and Extended Data Fig. 5d ), strongly supporting a role for CHD1 in H3K4me3 maintenance in prostate cancer. In addition, pathway analysis of either the genes concomitantly regulated by CHD1/H3K4me3 or the genes whose promoters are bound by CHD1 revealed a significant enrichment for genes involved in the TNF-NF-κ B network (Fig. 4c , Extended Data Fig. 5e and Supplementary Table 1, 2) .
Next, we performed microarray analysis in CHD1-depleted PC-3 and LNCaP cells (Supplementary Tables 3, 4) . The expression profiles of these cells aligned with the above ChIP-seq data, confirming that TNF-NF-κ B was the most downregulated hallmark pathway in CHD1-depleted cells (Fig. 4d and Extended Data Fig. 5f, g ). Of the 30 most downregulated genes in shCHD1 PC-3 cells, 10 were target genes of NF-κ B (Extended Data Table 1 ). Notably, pathway-enrichment analysis showed that the TNF-NF-κ B pathway is activated in PTEN-null mouse prostate tissue (Extended Data Fig. 5h ), suggesting that regulation of the TNF-NF-κ B network is linked to the PTEN-CHD1 axis.
NF-κ B is a key regulator of inflammation and plays important roles in prostate cancer initiation and progression 24 . Blockade of NF-κ B alone or in combination with anti-androgenic drugs suppresses tumour growth and metastasis in prostate cancer 25, 26 . Downregulated genes in the TNF-NF-κ B pathway that were identified by our microarray analysis include genes that control tumour cell proliferation (PTGS2) and apoptosis (IER3, BCL2 and SOD2), as well as multiple cytokines that remodel the tumour microenvironment (multiple CXCL genes, IL1 and IL6) 24 (Extended Data Fig. 5i ). These gene expression results were further validated by quantitative real-time PCR (qPCR) (Fig. 4h and Extended Data Fig. 5j ) and, upon analysis of clinical samples in the TCGA prostate cancer database, expression of these TNF-NF-κ B pathway genes was positively correlated with CHD1 expression (Extended Data Fig. 6a ). Although we identified many direct target genes of NF-κ B, we did not observe changes in levels of total or activated NF-κ B p65 on depletion of CHD1 (Fig. 4h and Extended Data Fig. 6b ). On the basis of CHD1 and H3K4me3 ChIP-seq data, all 90 downregulated genes in the TNF-NF-κ B pathway can be subdivided into three categories: (1) genes that are bound by CHD1 and marked by H3K4me3 (41.1%), consistent with CHD1 having direct transcriptional control of these genes, presumably via its interaction with the H3K4me3 mark; (2) genes that are not bound by CHD1 but that exhibit decreased H3K4me3 enrichment upon CHD1 depletion (47.8%), possibly reflecting CHD1-directed maintenance of the H3K4me3 modification, which activates target transcription; and (3) genes neither bound by CHD1 nor marked by H3K4me3 (approximately 10%), suggesting that they are indirectly regulated by CHD1 and H4K4me3 (Extended Data Fig. 6c and Extended Data Table 2 ). Thus, the majority (88.9%) of downregulated TNF-NF-κ B pathway genes are under the transcriptional control of CHD1, either directly or through its maintenance of the H3K4me3 modification. Finally, consistent with PTEN-CHD1-NF-κ B pathway epistasis, the enforced addition of several CHD1-target genes, such as PTGS2, BMP2 and CSF2, rescued colony formation in prostate cancer cells deficient in both PTEN and CHD1 (Extended Data Fig. 6d) .
Together, our data demonstrate that the epigenetic regulator CHD1 represents a prime therapeutic target candidate in PTEN-deficient prostate cancer, validating our in silico approach to identifying syntheticessential genes. Furthermore, our study identifies a novel PTEN pathway linking PTEN and chromatin-mediated regulation of the cancer-relevant NF-κ B network. Specifically, mechanistic analyses letter reSeArCH identified the PTEN-AKT-GSK3β -β -TrCP-mediated degradation of CHD1 via the ubiquitination-proteasome pathway (Extended Data  Fig. 7a ). In cancer, PTEN deficiency stabilizes CHD1, which engages and maintains the H3K4me3 modification to activate the expression of cancer-promoting genes, including those involved in the NF-κ B network, which is known to promote prostate cancer progression (Extended Data Fig. 7b ). In addition to prostate cancer, the mutually exclusive deletion pattern of PTEN and CHD1 is also present in breast and colorectal adenocarcinoma (Extended Data Fig. 7c ). To evaluate any potential roles for CHD1 in breast cancer, shRNA-mediated depletion was induced in two PTEN-deficient (BT-549 and MDA-MB-468) and two PTEN-intact (MDA-MB-231 and T47D) breast cancer cell lines. Consistent with the observations in prostate cancer, suppression of CHD1 inhibited the proliferation and tumour growth of PTENdeficient breast cancer (Extended Data Fig. 7d-f ), but had a minimal effect on PTEN-intact breast cancer cells (Extended Data Fig. 7g, h) . One caveat is the potential role of CHD1 as a key oncogenic driver in some cancer types, regardless of PTEN status. In such cancers, one would expect the consistent retention of CHD1 across genotypes.
Finally, we explored the generality of synthetic essentiality. To that end, we searched in silico for additional examples of candidate synthetic-essential genes that might have an obligate role in effecting carcinogenesis and tumour maintenance. Analysis of the prostate cancer TCGA database revealed a number of additional candidates that are rarely deleted but typically show increased expression in the context of alterations to specific tumour-suppressor genes, such as PTEN, TP53, SMAD4 and RB1 (Extended Data Table 3 ). Previous studies have shown that inhibiting these putative synthetic-essential genes could reduce cell proliferation or lead to tumour regression in prostate cancer and other cancer types, indicating their potential roles in synthetic-lethal interactions with putative tumour suppressors in a given cancer type. Further functional analyses will be needed to verify the synthetic essentiality of these genes in cancer cells that harbour specific tumour-suppressor deficiencies, as well as to identify potential regulatory interactions and cell-essential mechanisms.
Although most synthetic-lethal interactions involve two genes in parallel pathways that converge on the same essential biological process (for example, the convergence of BRCA and PARP on DNA-repair processes), the PTEN-CHD1 example indicates that the syntheticessential gene can serve as an essential downstream effector for a specific deficiency in a tumour-suppressor gene. Our results provide a framework for the discovery of targetable vulnerabilities in cancers harbouring specific tumour-suppressor deficiencies.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. ) was generated in 2010 as described previously 27 , and cultured in DMEM with 10% FBS. The prostate cancer cell lines RWPE-2 and PtenCaP8 were cultured in DMEM with 10% FBS, 25 μ g/ml bovine pituitary extract (BPE), 5 μ g/ml bovine insulin and 6 ng/ml human recombinant EGF. The breast cancer cell lines BT-549 and MDA-MB-468 were cultured with RPMI with 10% FBS; and the breast cancer cell line T47D was cultured with RPMI with 10% FBS and 5 μ g/ml bovine insulin. MDA-MB-231 and 293T cells were cultured in DMEM with 10% FBS. All cell lines were purchased from ATCC, confirmed to be mycoplasma-free, and maintained at 37 °C and 5% CO 2 . All human cell lines have been validated through fingerprinting by the MD Anderson Cell Line Core Facility.
All transient transfections of plasmids and siRNA into cell lines followed the standard protocol for Lipofectamine 2000 Transfection Reagent (Thermo Fisher, #11668019). Two siRNA oligos targeting β -TrCP were purchased from SigmaAldrich (SASI_Hs01_00189438 and 00189439). shRNA knockdown of CHD1. We screened seven hairpins targeting human CHD1 transcripts and found two independent sequences that reduced protein levels by > 70%. These hairpins were in the pLKO.1 vector (shCHD1 #2 and #4). The following CHD1 shRNA sequences were used: shCHD1 #2: NM_001270.2: 5′-CCGGGCGGTTTATCAAGAGCTATAACTCGAGTTATAGCTCTTGATA AACCGCTTTTT-3′; shCHD1 #4: NM_001270.2: 5′-CCGGGCGCA GTAGAAGTAGGAGATACTCGAGTATCTCCTACTTCTACTGCGCTTTTT-3′.
In addition, we screened five hairpins targeting mouse Chd1 and identified two that reduced protein levels by > 60%. These hairpins were in the pLKO.1 vector (shChd1 #1 and #2). The following mouse Chd1 shRNA sequences were used. shChd1 #1: NM_007690: 5′-CCGGTCCGAGCACACAC ATCATAAACTCGAGTTTATGATGTGTGTGCTCGGATTTTTG-3′; shChd1 #2: NM_007690: 5′-CCGGGCCAGGAGACATACAGTATTTCTCGA GAAATACTGTATGTCTCCTGGCTTTTTG-3′.
Recombinant lentiviral particles were produced by transient transfection of 293T cells. In brief, 8 μ g of the shRNA plasmid, 4 μ g of the psPAX2 plasmid, and 2 μ g of the pMD2.G plasmid were transfected using Lipofectamine 2000 into 293T cells plated in 100-mm dishes. Viral supernatant was collected 48 h and 72 h after transfection and filtered. Cells were infected twice in 48 h with viral supernatant containing 10 μ g/ml polybrene, and then selected using 2 μ g/ml puromycin and tested for CHD1 expression by immunoblot. Knockout using CRISPR. Short guide RNAs (sgRNAs) targeting human CHD1 were designed using the Broad Institute sgRNA Designer (http://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design) and cloned into pX330-Cherry vector individually. The CHD1 sgRNA sequences are as follows:
sgCHD1_#1F: 5′-CACCGGACGCATCATCAGACCAAA-3′; sgCHD1_#3F: 5′-CACCGTCAGCTCCATCAACTTTCGG-3′.
The plasmids with sgRNA were transiently transfected into cells using Lipofectamine 2000. Cells were harvested 72 h later, and ten Cherry-positive cells were sorted into each well of a 96-well plate by flow cytometry, followed by immunoblotting for CHD1 protein. PCR sequencing was also performed using genomic DNA extracted from CHD1-deficient single clones to identify genetic alteration at the CHD1 allele. Finally, we chose the single clone in which one or more premature stop codons were introduced in coding exons by sgRNA-induced mutations. An sgRNA plasmid targeting human PTEN was purchased from Santa Cruz Biotechnology (sc-400103); a similar process was performed to generate the PTEN-knockout DU145 cell line.
The re-expression of PTEN in PTEN-deficient cancer cells provoked proliferative arrest and apoptosis, given that PTEN regulates many hallmarks of cancer. Cell proliferation assays and apoptosis analysis. Cell proliferation was assayed either through colony formation or cell number counting. For the colony formation assay, 5 × 10 3 or 1 × 10 4 cells were seeded in each well of 6-well plates and cultured for 5-7 days. At the end point, cells were fixed and stained with 0.5% crystal violet in 25% methanol for 1 h. For cell number counting, 5 × 10 3 cells were seeded in each well of 6-well plates for each time point. At the indicated time points, cells were counted using a Countess II FL automated cell counter (Invitrogen). For apoptosis analysis, cells were stained with annexin V PE and DAPI, and evaluated by flow cytometry according to the manufacturer's protocol (Biovision). Xenograft prostate or breast cancer model. The in vivo tumour growth of human prostate or breast cancer cells transduced with a non-targeting hairpin or shCHD1 was determined using a subcutaneous transplant xenograft model. Cancer cells (2 × 10 6 ) in PBS/matrigel mixture were injected subcutaneously into 5-week-old male nude mice (Taconic) or NOD/SCID (non-obese diabetic/severe combined immunodeficient) mice (Charles River) under deep anaesthesia. The resulting tumours were measured twice a week. Once the largest tumour diameter reached the maximal tumour diameter allowed under our institutional protocol, all mice were killed and tumours were collected and weighed. For the PDX model, a PTENdeficient PDX line (MDA-prostate cancer-183, generated by N. M. Navone , mice were assigned randomly into one of two treatment groups. Each tumour was treated weekly (three times total) with 12 μ g control siRNA or siRNA targeting CHD1 using MaxSuppressor In Vivo RNALANCEr II (Bio Scientific, #3410-01), following the manufacturer's protocol. Tumour volume was measured before the first treatment (start point) and 3 days after the third treatment (end point). Both negative siRNA control (#VC30002) and human CHD1 siRNA (SASI_Hs02_00331472; 00203194; 00203195) were purified by high-performance liquid chromatography and purchased from Sigma-Aldrich. All mouse experiments were performed with the approval of the MD Anderson Institutional Animal Care and Use Committee (IACUC) under protocol number 1069. The maximal tumour diameter allowed by the IACUC is 1.5 cm. Immunoprecipitation and immunoblot. For CHD1 immunoprecipitation, cells were lysed in NP-40 buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.3% Nonidet P-40, and protease inhibitor cocktail (Sigma-Aldrich). Cell lysates (500 μ l) were incubated with anti-CHD1 antibody (Cell Signaling #4351S) or control IgG overnight at 4 °C. Magnetic or agarose beads (10 μ l, Novex, # 10003D) were added to each sample. After 3 h, the beads were washed three times with NP-40 buffer, followed by immunoblotting. For V5-immunoprecipitation, cell lysates were incubated with anti-V5-tag mAb-magnetic beads (MBL International, #M167-9) for 3 h at 4 °C. For the ubiquitination assay, 48 h after transfection, cells were lysed in 1% SDS buffer (50 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 1 mM DTT) and boiled for 15 min, followed by a fivefold dilution in 50 mM Tris-HCl immunoprecipitation buffer. Proteins were blotted following standard protocol. Antibodies specific for CHD1 (Cell Signaling, #4351S), PTEN (Cell Signaling, #9188S), S473P-AKT (Cell Signaling, #3787S), β -TrCP (Cell Signaling, #4394S), H3K4me3 (Cell Signaling, #9751S), Flag (Sigma, #F7425), HA (Santa Cruz, #sc-7392), GSK3β (Cell Signaling, #12456P), and β -actin (Sigma, #A3854) were purchased from the indicated companies. Phos-tag SDS-PAGE (Wako Chemicals, SuperSep Phos-tag, #192-17401) was used to detect phosphorylation of CHD1 following the standard protocol. Immunohistochemistry and immunofluorescence. Eighty cases of human prostate hyperplasia and cancer samples were purchased from US Biomax (PR807b) and the rest of the samples were acquired from the Prostate Tissue Bank of MD Anderson Cancer Center (total n = 127). Immunohistochemistry was performed as previously described 27 . A pressure cooker (95 °C for 30 min followed by 120 °C for 10 s) was used for antigen retrieval using Antigen Unmarking Solution (Vector Laboratories). Antibodies specific to CHD1 (Sigma, #HPA022236) and PTEN (Cell Signaling, #9188S) were purchased. The human tissue sections were reviewed and scored in a blinded manner for staining intensity (0-2) by W.L. High expression of CHD1 corresponded to a staining score of 2, whereas low expression corresponded to staining scores 0 and 1. Slides were scanned using Pannoramic 250 Flash III (3DHISTECH Ltd) and images were captured through Pannoramic Viewer software (3DHISTECH Ltd). Procedures related to human specimens were approved by the MD Anderson Institutional Review Board under protocol number #PA14-0420; human samples from MD Anderson tissue banks were obtained with the informed consent from the patients for tissue collection for research purposes.
PC-3 cells were infected with GFP-PTEN lentiviral particles for 72 h, fixed and stained using anti-CHD1 antibodies (Sigma, #HPA022236) following the standard protocol. Images were captured using a fluorescence microscope (Leica DMi8). Migration assay. Prostate cancer cells (1 × 10 4 ) were suspended in serum-free culture medium and seeded into 24-well Transwell inserts (8.0 μ m). Medium with serum was added to the remaining receiver wells. After 24 h, the inside of each insert was gently swabbed, and crystal violet solution was added for 1 h for staining. ChIP-seq. ChIP was performed as described 29 . Briefly, chromatin from formaldehydefixed cells (control and CHD1-knockdown PC-3 cells, 1 × 10 7 cells for anti-CHD1 antibody and 1 × 10 6 cells for anti-H3K4me3 antibody) were cross-linked using 1% paraformaldehyde for 10 min and reactions were quenched by addition of 0.125 M glycine for 5 min at room temperature. Cells were lysed with ChIP lysis buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0), 140 mM NaCl, 1% Triton X-100, 0.2% SDS, 0.1% deoxycholic acid) for 30 min on ice. Chromatin fragmentation was performed using a Diagenode BioruptorPico sonicator (30 s on, 30 s off for 45 cycles) to achieve a DNA shear length of 200-500 bp. Solubilized chromatin letter reSeArCH was then incubated overnight with the appropriate antibody-Dynabead (Life Technologies) mixture (anti-CHD1 antibody: Bethyl, #A301-218A; anti-H3K4me3 antibody: Abcam, #ab8580). Immune complexes were then washed three times with RIPA buffer, once with RIPA-500 (RIPA with 500 mM NaCl), and once with LiCl wash buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0), 250 mM LiCl, 0.5% NP-40, 0.5% deoxycholic acid). Elution and reverse-crosslinking were performed in direct elution buffer (10 mM Tris-Cl (pH 8.0), 5 mM EDTA, 300 mM NaCl, 0.5% SDS) with proteinase K (20 mg/ml) at 65 °C overnight. Eluted DNA was purified using AMPure beads (Beckman-Coulter). Libraries were prepared using NEBNext Ultra DNA Library kit (E7370). Sequencing was performed using an Illumina HiSeq 2500 instrument to generate dataset GSE91401. Reads were aligned to a reference genome (UCSC hg19; http://hgdownload.cse.ucsc.edu/downloads. html#human) using the Burrows-Wheeler Aligner. Reads mapping to more than two genomic loci were ignored. mRNA expression analysis and microarray. Cells were lysed in TRIzol Reagent (Invitrogen; #15596-026), followed by total RNA isolation using the standard protocol. The RNA was further purified using RNeasy (QIAGEN) according to the manufacturer's protocol and reverse-transcribed into cDNA using the SuperScript III First-Strand Synthesis System (Invitrogen). qPCR was performed for target-gene-expression analysis using the SYBR Green PCR Master Mix (Applied Biosystems); indicated primers are listed in Supplementary Table 5 . Microarray analysis was performed on RNA prepared from control and CHD1-knockdown PC-3 or CHD1-knockout LNCaP cells (biological triplicates for control and each CHD1 shRNA or CHD1-knockout) at the MD Anderson Microarray Core facility using the GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix) to generate dataset GSE84970. Genes that were differentially expressed between control and CHD1-depleted groups were subjected to ingenuity pathway analysis (IPA) and gene set enrichment analysis (GSEA). The GSE25140 dataset, published in 2011, of wild-type and Pten deletion mouse prostate tissues was downloaded from the NCBI GEO database repository 27 . The raw data were processed and analysed by GenePattern using Expression File Creator Module (version 12.3) and GSEA module (v17). The default GSEA basic parameters were used and a t-test was used as the metric for ranking genes. Computational analysis of human prostate TCGA data. A list of 60 downregulated genes (fold change > 2) in the TNF-NF-κ B pathway identified by microarray analysis was generated (Extended Data Table 2 ). The mRNA expression z scores of each gene in 498 TCGA prostate cancer samples were downloaded from http:// www.cbioportal.org. The two-tailed Pearson correlations between CHD1 expression and indicated genes were calculated using SPSS Statistics software (IBM), and P values were determined by two-tailed Fisher's exact test. The gene list was then ranked by Pearson's correlation with CHD1 expression. The heat map was generated using Microsoft Excel Graded Colour Scale function with a threecolour scale set at numbers − 1, 0, and 1. For the analysis of mutual exclusiveness and gene expression listed in Extended Data Table 3 , the genetic alteration and gene expression of 332 TCGA prostate cancer samples with mRNA, copy number alterations and sequencing data were downloaded from http://gdac.broadinstitute. org/runs/stddata__2016_01_28/data/PRAD/20160128/ and analysed. The odds ratio score was calculated to indicate mutual exclusiveness between gene A and gene B deletion. The mean values of gene B expression in all 332 samples and that in gene A deleted samples were calculated, and P values were determined by twotailed student t-test. Statistics. Images of genomic alterations in TCGA database were captured from http://www.cbioportal.org. Estimations of sample size were done taking into consideration previous experience with animal strains, assay sensitivity and tissue collection methodology used. The two-tailed Pearson correlation between CHD1 and PTEN expression or Gleason grades was calculated using SPSS Statistics software (IBM), and P values were determined by two-tailed Fisher's exact test. The Student t-test assuming two-tailed distributions was used to calculate statistical significance between groups (GraphPad Prism 6 or Microsoft Excel). The n value represents biological replicates. Error bars indicate standard deviation (s.d.). The P values shown in the tumour growth plot ( Fig. 1 and Extended Data Figs 2, 3, 7) indicate the differences in tumour sizes at the end-point. For IPA, we included all 50 'hallmark' gene sets of the Molecular Signatures Database (MSigDB) as described 30 as customized pathways. Then a list of downregulated genes in CHD1-knockdown PC-3 cells generated from microarray (Supplementary Table 3 ) or the peak-score list generated from ChIP (Supplementary Table 1 or 2) was uploaded for IPA core analysis. The filter threshold of microarray data was a fold change (control versus shCHD1) > 1.5. Data availability. The Microarray dataset generated during the current study has been deposited in the Gene Expression Omnibus (GEO) repository under accession number GSE84970. The ChIP-seq dataset generated in this study has been deposited in GEO repository under accession number GSE91401. The ChIPseq signal annotated file and alternatively expressed genes lists (fold change > 1.5) generated in this study are included in this published article (and its Supplementary Information). Relevant TCGA datasets were downloaded from http://gdac. broadinstitute.org/runs/stddata__2016_01_28/data/PRAD/20160128/ or http://www.cbioportal.org. All other data are available from the corresponding author upon reasonable request. 
letter reSeArCH extended Data table 3 | Mutual exclusiveness pairs in prostate cancer
Gene A (PTEN, TP53, SMAD4 and RB1) represents the most common altered tumour suppressors in prostate cancer. For each gene in the Gene B list the table shows: (1) mutual exclusiveness score (odds ratio score) with Gene A; (2) Gene B expression in Gene A-deleted prostate cancer samples (P < 0.1); and (3) proposed functions in cancer progression. P values were determined by two-tailed t-test.
